Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ACCEL-RIZATRIPTAN ODT - Health Canada Drug Approval Details

Approvals/Health Canada/ACCEL-RIZATRIPTAN ODT

Authorized

STANDARD

ACCEL-RIZATRIPTAN ODT

ACCEL PHARMA INC🇨🇦 Health Canada

Approval Date: Apr 6, 2026
Approval ID: 9b07168a2ac01017
Company: ACCEL PHARMA INC
Type: Standard

Approval Details

Approval Id: 9b07168a2ac01017
Drug Approval Canada Name: ACCEL-RIZATRIPTAN ODT
Product Name: ACCEL-RIZATRIPTAN ODT
Status: Marketed
Status Date: 2019-10-07
Original Market Date: 2019-10-07
Drug Class: Human
Dosage Form: Tablet (Orally Disintegrating)
Route Of Administration: Oral
Schedule: PRESCRIPTION
Ahfs: 28:32.28
Atc Original: N02CC04 RIZATRIPTAN
Aig Number: 0137841002
Company Name: ACCEL PHARMA INC
Company Address: 119 Labrosse Ave Pointe Claire Quebec Canada H9R 1A3

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Apr 6, 2026

Approval ID

9b07168a2ac01017

Type

Standard

Back to Health Canada Approvals